Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a consent form
- People who are willing to follow all study procedures and remain available for the full duration of the study
- People aged 18 to 100 years, of any gender
- People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer), confirmed through laboratory testing of tissue or cells
- People who have had specialised genetic testing of their cancer performed through an approved laboratory method, using either a tissue sample or a blood sample
- People whose general physical condition and ability to carry out daily activities falls within a certain range, as rated by their doctor (confirm with trial site)
- People for whom a doctor has already decided on a specific standard cancer treatment, such as a targeted therapy tablet or chemotherapy, with or without immunotherapy, before joining the study
- People who are planned to receive a bone-strengthening medication and have received dental clearance from a dentist before starting that treatment
- People whose cancer has spread to the bones, with this confirmed through medical scans before joining the study
Who may not be able to join:
- People with a specific type of non-small cell lung cancer driven by an identifiable genetic mutation who have already taken certain bone-protective medications, including zolendronic acid, pamidronate, alendronate, denosumab, or similar drugs that affect bone cells
- People with any other health condition that, in the opinion of the study doctor, could put them at risk or affect how they respond to their standard cancer treatment
- People with a specific genetic mutation driving their lung cancer who have previously taken or are currently taking a type of targeted therapy called a TKI (a specific class of cancer treatment tablet)
- People whose bone metastases have previously been treated with radiation therapy, unless there is clear evidence that the cancer has continued to grow since that radiation treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Erin Schenk, MD, University of Colorado, Denver
Phone: 13037249459
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage reduction of urine NTX and serum CTX
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.